QBiotics
QBiotics is an Australian life sciences company specializing in the discovery and development of novel cell signaling small molecules for complex medical conditions, with a focus on oncology and wound healing. They apply phenotypic screening and have strategic research partnerships worldwide. Their mission is to improve lives globally through innovative pharmaceuticals derived from nature.
Industries
Nr. of Employees
small (1-50)
QBiotics
PO Box 42, Toowong BC, QLD 4066, Australia
Patents
Products
Intratumoural small‑molecule oncology candidate (human development)
A plant‑derived small‑molecule candidate administered by intratumoural injection being developed for treatment of a range of solid tumours; has progressed through first‑in‑human studies and into Phase II clinical trials.
Registered veterinary intratumoural oncology product (commercialized formulation)
A veterinary formulation of an intratumoural small‑molecule oncology therapeutic that is registered and marketed for veterinary use across multiple regions via a commercial partner.
Wound‑healing small‑molecule candidate (early clinical)
A small‑molecule candidate targeting chronic and acute wounds and burns, advanced to first‑in‑human Phase I safety trials for venous leg ulcers.
Preclinical anti‑virulence antibiotic discovery programme
Discovery‑stage programme focused on small molecules that inhibit bacterial virulence as an alternative antibiotic approach.
Intratumoural small‑molecule oncology candidate (human development)
A plant‑derived small‑molecule candidate administered by intratumoural injection being developed for treatment of a range of solid tumours; has progressed through first‑in‑human studies and into Phase II clinical trials.
Registered veterinary intratumoural oncology product (commercialized formulation)
A veterinary formulation of an intratumoural small‑molecule oncology therapeutic that is registered and marketed for veterinary use across multiple regions via a commercial partner.
Wound‑healing small‑molecule candidate (early clinical)
A small‑molecule candidate targeting chronic and acute wounds and burns, advanced to first‑in‑human Phase I safety trials for venous leg ulcers.
Preclinical anti‑virulence antibiotic discovery programme
Discovery‑stage programme focused on small molecules that inhibit bacterial virulence as an alternative antibiotic approach.
Services
Collaborative biodiscovery programmes applying phenotypic screening to rainforest‑derived molecular scaffolds to identify small‑molecule leads.
End‑to‑end preparation of preclinical and CMC documentation, IND submissions, and management of early‑phase clinical trials (Phase I–II) including translational research objectives.
Partner‑led commercialization of veterinary pharmaceutical formulations with regional market approvals and launch support.
Collaborative biodiscovery programmes applying phenotypic screening to rainforest‑derived molecular scaffolds to identify small‑molecule leads.
End‑to‑end preparation of preclinical and CMC documentation, IND submissions, and management of early‑phase clinical trials (Phase I–II) including translational research objectives.
Partner‑led commercialization of veterinary pharmaceutical formulations with regional market approvals and launch support.
Expertise Areas
- Clinical trial management (Phase I–II)
- Biodiscovery of natural product small molecules
- Translational research and tumour microenvironment analysis
- Veterinary‑to‑human translational development
Key Technologies
- Phenotypic drug screening
- Rainforest‑derived natural product biodiscovery
- Small‑molecule drug discovery
- Intratumoural drug delivery
News & Updates
31 December 2024 Interim Financial Report
The interim financial report for the six months ended 31 December 2024, approved by the Board, is available for viewing/download.
February 2024 Shareholder Update
The shareholder update for February 2024 is available for viewing/download.
August 2024 Shareholder Update
The shareholder update for August 2024 is available for viewing/download.
Bell Potter Healthcare Conference presentation
QBiotics CEO Stephen Doyle provided an update on the company's programs at the Bell Potter Healthcare Conference.
Board and Executive changes at QBiotics Group
Announcement of strategic review, appointment of Dr. Sue Foden as Executive Chair, and other leadership changes.
2024 Annual General Meeting - CEO Presentation and Results
The AGM was held on 22 November 2024, with presentation and results available.
31 December 2024 Interim Financial Report
The interim financial report for the six months ended 31 December 2024, approved by the Board, is available for viewing/download.
February 2024 Shareholder Update
The shareholder update for February 2024 is available for viewing/download.
August 2024 Shareholder Update
The shareholder update for August 2024 is available for viewing/download.
Bell Potter Healthcare Conference presentation
QBiotics CEO Stephen Doyle provided an update on the company's programs at the Bell Potter Healthcare Conference.
Board and Executive changes at QBiotics Group
Announcement of strategic review, appointment of Dr. Sue Foden as Executive Chair, and other leadership changes.
2024 Annual General Meeting - CEO Presentation and Results
The AGM was held on 22 November 2024, with presentation and results available.